Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Physiological Dissection of the Mevalonate Pathway

Award Number: R01DK124477
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/06/2020
PERIOD OF PERFORMANCE END DATE: 02/28/2030

Group Awards By:

View Award Description

Physiological Dissection of the Mevalonate Pathway - PROJECT SUMMARY The mevalonate pathway is responsible for the de novo synthesis of cholesterol and other biologically important isoprenoids from acetyl-CoA. Rates of cholesterol synthesis vary greatly amongst different cell types in the body. The long term goal of this project is to better understand the physiological function and regulation of the mevalonate pathway in different tissues. The intestine occupies the critical interface for cholesterol absorption and excretion from the body. Interestingly, the human intestine synthesizes more cholesterol per gram of tissue than the liver, suggesting important tissue and cell-type specific needs for this metabolite. Cholesterol is a critical component of cellular membranes, which is in high demand by intestinal stem cells (ISC) that continuously divide to replenish the epithelial surface of the villi every 3-5 days. In addition, since mammals do not have a catabolic pathway for cholesterol, its only route of disposal is through excretion in the feces. We will address key gaps in knowledge in terms of how de novo cholesterol synthesis impacts ISC activity, as well as interfaces with the opposing processes of cholesterol absorption and excretion by enterocytes. In this competing renewal R01 application, we will use genetically engineered mouse models and primary human organoids to elucidate the physiological function of the mevalonate pathway in the intestine. Cholesterol synthesis is controlled by the rate- limiting enzyme 3-hydroxy-3-methylglutaryl Coenzyme A reductase (Hmgcr), the target of the statin drugs. We recently generated mice with intestine-specific deletion of Hmgcr (Vil1-Cre) to genetically ablate the pathway. Loss of Hmgcr revealed an unexpected effect on stem cell homeostasis, with a doubling of the resident stem cell compartment. We also found that enterocytes are able to preserve cholesterol levels in the absence of synthesis, most likely through greater uptake of lipoprotein cholesterol, accompanied by increased cholesterol in the feces. Based on these findings, we hypothesize that the loss of Hmgcr drives a program of stem cell self-renewal and expansion, mediated by increased sterol regulatory element binding protein 2 (SREBP-2) activity. We also hypothesize that inhibition of cholesterol synthesis in the absorptive epithelial surface drives lipoprotein uptake from the basolateral surface, promoting trans-intestinal cholesterol excretion (TICE) and removal from the body. In this project we will 1) Determine the mechanism for stem cell expansion following loss of Hmgcr in the intestine, and 2) Determine if mevalonate pathway inhibition in enterocytes promotes cholesterol elimination. Results from this project will provide valuable insights into the regulation of the intestinal stem cell niche by cholesterol, and improve our understanding of how enterocyte cholesterol synthesis controls cholesterol balance.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $697,794 )
2026	2026	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	6	2/9/2026	NON-COMPETING CONTINUATION	$697,794
														Subtotal = $697,794

Issue Date FY: 2025 ( Subtotal = $720,822 )
2025	2025	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	5/7/2025	COMPETING CONTINUATION	$720,822
2025	2023	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	4	6/25/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $720,822

Issue Date FY: 2023 ( Subtotal = $532,092 )
2023	2023	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	2/23/2023	NON-COMPETING CONTINUATION	$532,092
														Subtotal = $532,092

Issue Date FY: 2022 ( Subtotal = $532,092 )
2022	2022	BAYLOR COLLEGE OF MEDICINE	ONE BAYLOR PLAZA	HOUSTON	TX	77030	HARRIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	2/23/2022	NON-COMPETING CONTINUATION	$478,883
2022	2022	BAYLOR COLLEGE OF MEDICINE	ONE BAYLOR PLAZA	HOUSTON	TX	77030	HARRIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	3/29/2022	NON-COMPETING CONTINUATION	$53,209
														Subtotal = $532,092

Issue Date FY: 2021 ( Subtotal = $532,092 )
2021	2021	BAYLOR COLLEGE OF MEDICINE	ONE BAYLOR PLAZA	HOUSTON	TX	77030	HARRIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	2/25/2021	NON-COMPETING CONTINUATION	$532,092
														Subtotal = $532,092

Issue Date FY: 2020 ( Subtotal = $532,022 )
2020	2020	BAYLOR COLLEGE OF MEDICINE	ONE BAYLOR PLAZA	HOUSTON	TX	77030	HARRIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	4/7/2020	NEW	$532,022
														Subtotal = $532,022

Grand Total All Awards = $3,546,914

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Physiological Dissection of the Mevalonate Pathway

Award Number: R01DK124477

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/06/2020

PERIOD OF PERFORMANCE END DATE: 02/28/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer